Kite acquisition signals Gilead’s leadership and continued consolidation moving forward, says Katherine Xu
William Blair analyst Y Katherine Xu is out with a bullish note on shares of Dynavax Technologies Corporation (NASDAQ:DVAX), after the FDA’s Vaccines and Related Biological …
Synthetic Biologics Inc (NYSEMKT:SYN) shares were rising almost 29% yesterday as the news took off that the biotech firm won a Breakthrough Therapy …
Synthetic Biologics Inc (NYSEMKT:SYN) is steaming right along with key programs gearing toward pivotal studies. Despite financing continuing to be the real stand-out …
Synthetic Biologics Inc (NYSEMKT:SYN) revealed Wednesday, January 18th after market close that the FDA has green-lighted its Phase IIb/III adaptive trial design of …
Achaogen Inc (NASDAQ:AKAO) shares rose 14% today after the company reported positive top-line results from the phase 3 trial of its treatment for urinary …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) recently presented updated data from the pivotal ALTA trial of brigatinib in refractory ALK+ non–small-cell lung cancer (NSCLC) was …
That was a rough week for investors in Dynavax Technologies Corporation (NASDAQ:DVAX), after the biotech firm announced on Monday, November 14th that it had received …
William Blair analyst Y Katherine Xu is out with a research report on shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) after having recently updated …
Dynavax Technologies Corporation (NASDAQ:DVAX) shares have tumbled recently on the heels of last Friday’s FDA announcement of the cancellation of the November 16, 2016 …
